Precigen to report first quarter 2024 financial results after the market close on Tuesday, May 14, 2024.

Precigen to participate in the 2024 COSM annual meeting taking place in Chicago from May 15 to May 19, 2024. On May 16 at 4:21 PM CT, Dr. Clint T. Allen, MD, Principal Investigator with the Section on Translational Tumor Immunology at the National Institutes of Health and a lead investigator for the PRGN-2012 clinical study, will present "Clinical Benefit following Adjuvant Therapeutic Vaccination with PRGN-2012 in Adult Patients with RRP."

Abstract Selected for Late-Breaking Oral Presentation

• June 3, 2024 | 8:00 AM - 9:30 AM CT
  PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients
  Abstract: 6015 | Rapid Oral Abstract Session - Head and Neck Cancer

Abstracts Selected for Poster Presentation

• June 2, 2024 | 9:00 AM - 12:00 PM CT
  Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer
  Abstract: 6124 | Poster Session - Head and Neck Cancer
• June 3, 2024 | 9:00 AM - 12:00 PM CT
  A Phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer
  Abstract 5623 | Poster Session - Gynecologic Cancer